KURA
Kura Oncology, Inc. · Healthcare
8.82
3.89%(+0.33)
Close9.03
2.38%(+0.21)
After HoursLast Updated: — ET
52W L: $5.4552W H: $12.49
$8.80
CHG-0.16 (-1.79%)
H$9.58
L$7.55
VOL23M
KURA (1h)
Kura Oncology, Inc. · Healthcare
SG Americas Securities LLC grew its stake in Kura Oncology, Inc. (NASDAQ: KURA) by 214.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,715 shares of the company's stock after buying an additional 103,411 shares during the period.
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (KURA) is reiterated as a Strong Buy, leveraging Komzifti's differentiated safety profile and substantial cash position for asymmetric upside. KURA's 2026 revenue expectations are achievable, requiring only 16% market penetration in NPM1-m R/R AML, supported by rapid payer coverage and favorable launch dynamics. The partnership with Kyowa Kirin caps upside but de-risks execution, with KURA booking all US sales and benefiting from milestone payments and cost sharing.
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology (NASDAQ: KURA) executives used the company's fourth-quarter and fiscal 2025 earnings call to highlight what CEO Troy Wilson called a "defining year," driven by the FDA approval of Komzifti and the start of its U.S. commercial launch. Management said early prescription trends and market access have exceeded internal expectations, while the company advances a
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
WILSON TROY EDWARD
director, officer: President and CEO
6,103 SH @ $6.15
2026-03-23
WILSON TROY EDWARD
director, officer: President and CEO
6,103 SH @ $6.15
2026-03-23
Malley Thomas
director
10,000 SH @ $3.12
2026-03-18
Malley Thomas
director
10,000 SH @ $3.12
2026-03-18
Powl Brian T.
officer: Chief Commercial Officer
4,842 SH @ $8.46
2026-01-27
Powl Brian T.
officer: Chief Commercial Officer
1,572 SH @ $8.46
2026-01-27
FORD KATHLEEN
officer: Chief Operating Officer
1,813 SH @ $8.46
2026-01-27
Leoni Mollie
officer: Chief Medical Officer
3,655 SH @ $8.46
2026-01-27